Substitute Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-16 (canceled).

17. (currently amended) A method for treating a subject with a Parkinsonian-type neurodegenerative disorder, comprising:

administering to said subject ~~a biologically effective amount of~~ at least one α_{1B} adrenergic receptor antagonist, wherein administration of said antagonist tempers the severity of the disorder or the symptoms associated therewith ~~a compound capable of blocking activation of α_{1B} adrenergic receptors~~.

Claims 18-21 (canceled).

22. (New) The method of claim 17, wherein the at least one α_{1B} adrenergic receptor antagonist is selected from the group consisting of terazosin, prazosin, 5 methylurapidil, WB 4101, niguldipine, HEAT, indoramine, coryanthine, spierone, benoxathian, spriorxatrine, and chloroethylclonidined.

23. (New) The method of claim 22, wherein the at least one α_{1B} adrenergic receptor antagonist is terazosin.

24. (New) The method of claim 22, wherein the at least one α_{1B} adrenergic receptor antagonist is prazosin.

25. (New) The method of claim 22, wherein the at least one α_{1B} adrenergic receptor antagonist is 5 methylurapidil.

26. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is WB 4101.

27. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is niguldipine.

28. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is HEAT.

29. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is indoramine,

30. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is coryanthine.

31. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is spierone.

32. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is benoxathian.

33. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is spriorxatrine.

34. (New) The method of claim 22, wherein the at least one α1B adrenergic receptor antagonist is chloroethylclonidined.

35. (New) A method for treating a subject with a neurodegenerative disorder that involves epileptic seizures, comprising:

administering to said subject a compound that binds to and blocks activation of α_{1B} adrenergic receptors, wherein administration of said compound lessens the severity of the disorder or the symptoms associated therewith.

36. (New) The method of claim 35 wherein said compound is selected from the group consisting of terazosin, prazosin, 5 methylurapidil, WB 4101, niguldipine, HEAT, indoramine, coryanthine, spierone, benoxathian, spriorxatrine, and chloroethylclonidined

37. (New) The method of claim 35, wherein the compound is terazosin.

38. (New) A method for treating a subject with a tryosine hydroxylase-deficiency disorder, comprising:

administering to said subject a compound that binds to and blocks activation of α_{1B} adrenergic receptors, wherein administration of said compound lessens the severity of the disorder or the symptoms associated therewith.

39. (New) The method of claim 38 wherein said compound is selected from the group consisting of terazosin, prazosin, 5 methylurapidil, WB 4101, niguldipine, HEAT, indoramine, coryanthine, spierone, benoxathian, spriorxatrine, and chloroethylclonidined